Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 217

1.

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, Janes H, Morris D, Fong Y, Edlefsen PT, Li F, Frahm N, Alpert MD, Prentice H, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Robb ML, O'Connell RJ, Haynes BF, Michael NL, Kim JH, McElrath MJ, Geraghty DE.

J Clin Invest. 2014 Sep 2;124(9):3879-90. doi: 10.1172/JCI75539. Epub 2014 Aug 8.

PMID:
25105367
[PubMed - in process]
Free PMC Article
2.

HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.

Seaton KE, Ballweber L, Lan A, Donathan M, Hughes S, Vojtech L, Moody MA, Liao HX, Haynes BF, Galloway CG, Richardson BA, Karim SA, Dezzutti CS, McElrath MJ, Tomaras GD, Hladik F.

PLoS One. 2014 Jul 23;9(7):e101863. doi: 10.1371/journal.pone.0101863. eCollection 2014.

PMID:
25054205
[PubMed - in process]
Free PMC Article
3.

Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials.

Hensley-McBain T, Heit A, De Rosa SC, McElrath MJ, Andersen-Nissen E.

J Immunol Methods. 2014 Jun 9. pii: S0022-1759(14)00184-7. doi: 10.1016/j.jim.2014.06.002. [Epub ahead of print]

PMID:
24925805
[PubMed - as supplied by publisher]
4.

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, deCamp AC, Magaret CA, Ahmed H, Goodridge JP, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, Sidney J, Sette A, Zolla-Pazner S, Montefiori D, McElrath MJ, Mullins JI, Kim JH, Gilbert PB, Hertz T.

J Virol. 2014 Aug;88(15):8242-55. doi: 10.1128/JVI.01164-14. Epub 2014 May 14.

PMID:
24829343
[PubMed - in process]
Free PMC Article
5.

Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships.

Mujugira A, Celum C, Thomas KK, Farquhar C, Mugo N, Katabira E, Bukusi EA, Tumwesigye E, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):436-42. doi: 10.1097/QAI.0000000000000192.

PMID:
24798765
[PubMed - indexed for MEDLINE]
6.

Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception.

Murnane PM, Heffron R, Ronald A, Bukusi EA, Donnell D, Mugo NR, Were E, Mujugira A, Kiarie J, Celum C, Baeten JM; Partners PrEP Study Team.

AIDS. 2014 Jul 31;28(12):1825-30. doi: 10.1097/QAD.0000000000000290.

PMID:
24785951
[PubMed - in process]
7.

Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal.

Ducar C, Smith D, Pinzon C, Stirewalt M, Cooper C, McElrath MJ, Hural J; NIAID HIV Vaccine Trials Network.

J Immunol Methods. 2014 Jul;409:9-20. doi: 10.1016/j.jim.2014.03.024. Epub 2014 Apr 4.

PMID:
24709391
[PubMed - in process]
8.

Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells.

Mitchell CM, McLemore L, Westerberg K, Astronomo R, Smythe K, Gardella C, Mack M, Magaret A, Patton D, Agnew K, McElrath MJ, Hladik F, Eschenbach D.

J Infect Dis. 2014 Aug 15;210(4):651-5. doi: 10.1093/infdis/jiu176. Epub 2014 Mar 20.

PMID:
24652495
[PubMed - in process]
9.

One shot forward for HIV prevention.

Corey L, McElrath MJ.

Nat Med. 2014 Mar;20(3):241-2. doi: 10.1038/nm.3503. No abstract available.

PMID:
24603794
[PubMed - indexed for MEDLINE]
10.

Challenges and responses in human vaccine development.

Kaufmann SH, McElrath MJ, Lewis DJ, Del Giudice G.

Curr Opin Immunol. 2014 Jun;28:18-26. doi: 10.1016/j.coi.2014.01.009. Epub 2014 Feb 19.

PMID:
24561742
[PubMed - in process]
Free Article
11.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team.

Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.

PMID:
24560541
[PubMed - indexed for MEDLINE]
12.

Variants in host viral replication cycle genes are associated with heterosexual HIV-1 acquisition in Africans.

Bigham AW, Mackelprang RD, Celum C, De Bruyn G, Beima-Sofie K, John-Stewart G, Ronald A, Mugo NR, Buckingham K, Bamshad MJ, Mullins JI, McElrath MJ, Lingappa JR.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):127-34. doi: 10.1097/QAI.0000000000000113.

PMID:
24463784
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study.

McKinnon LR, Hughes SM, De Rosa SC, Martinson JA, Plants J, Brady KE, Gumbi PP, Adams DJ, Vojtech L, Galloway CG, Fialkow M, Lentz G, Gao D, Shu Z, Nyanga B, Izulla P, Kimani J, Kimwaki S, Bere A, Moodie Z, Landay AL, Passmore JA, Kaul R, Novak RM, McElrath MJ, Hladik F.

PLoS One. 2014 Jan 15;9(1):e85675. doi: 10.1371/journal.pone.0085675. eCollection 2014.

PMID:
24454917
[PubMed - in process]
Free PMC Article
14.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network.

J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

PMID:
24403557
[PubMed - indexed for MEDLINE]
15.

Measuring inhibition of HIV replication by ex vivo CD8⁺ T cells.

Slichter CK, Friedrich DP, Smith RJ, Walsh PN, Mize G, Czartoski JL, McElrath MJ, Frahm N.

J Immunol Methods. 2014 Feb;404:71-80. doi: 10.1016/j.jim.2013.12.006. Epub 2013 Dec 25.

PMID:
24374374
[PubMed - indexed for MEDLINE]
16.

Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan Africans.

Mackelprang RD, Bigham AW, Celum C, de Bruyn G, Beima-Sofie K, John-Stewart G, Ronald A, Mugo NR, Buckingham KJ, Bamshad MJ, Mullins JI, McElrath MJ, Lingappa JR.

J Infect Dis. 2014 May 15;209(10):1623-7. doi: 10.1093/infdis/jit807. Epub 2013 Dec 10.

PMID:
24325963
[PubMed - indexed for MEDLINE]
17.

Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication.

Sunshine J, Kim M, Carlson JM, Heckerman D, Czartoski J, Migueles SA, Maenza J, McElrath MJ, Mullins JI, Frahm N.

J Virol. 2014 Jan;88(2):1354-65. doi: 10.1128/JVI.02361-13. Epub 2013 Nov 13.

PMID:
24227851
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.

N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

PMID:
24099601
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.

Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, Fife KH, Delany-Moretlwe S, de Bruyn G, Bukusi EA, Karita E, Kapiga S, Corey L, Wald A; Partners in Prevention HSV/HIV Transmission Study Team.

J Infect Dis. 2013 Nov 1;208(9):1366-74. doi: 10.1093/infdis/jit333. Epub 2013 Jul 30.

PMID:
23901094
[PubMed - indexed for MEDLINE]
20.

Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.

Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, Casimiro DR, Carrington M, Geraghty DE, Gilbert PB, McElrath MJ, Frahm N.

J Infect Dis. 2013 Oct 15;208(8):1231-9. doi: 10.1093/infdis/jit322. Epub 2013 Jul 21.

PMID:
23878319
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk